Akorn (AKRX) Guides FY13 adj.-EPS Below Views, Revs In-Line; Reaffirms FY12 - InvestingChannel

Akorn (AKRX) Guides FY13 adj.-EPS Below Views, Revs In-Line; Reaffirms FY12

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

Top News Most Read Highlighted

Get Alerts AKRX Hot Sheet

Financial Fact:

Today’s EPS Names:

WABC, CZFC, RBCAA, More

Akorn, Inc. (NASDAQ: AKRX), a niche pharmaceutical company, today provided full year 2013 financial guidance. The Company’s guidance excludes the impact from any products for which the Company has not yet received FDA approval. The Company will provide a more detailed update during its year-end 2012 conference call.

Total revs of $325 million to $335 million. The Street is at $330.7 million.

SG&A expenses of $51 million to $54 million.

Adjusted net income per share of 57 cents to 61 cents. The Street is at 66 cents.

CapEx of about $25 million.

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW